
Ligand Pharmaceuticals Incorporated
LGND
Updated: 23/09/2026, 00:33:10
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
No summaries found.
- Share price
- $298.50
- Market cap
- $5.98B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Todd C. Davis
- Employees
- 47
- IPO date
- 18/11/1992
- Beta
- 0.976
- Last dividend
- $0.00
- Day range
- $289.00 – $300.48
- 52-week range
- $163.45 – $326.63
- 1-day performance
- 2.91%
- 1-year performance
- 82.62%
- Current drawdown (1Y)
- -8.61%
- CIK
- 0000886163
- CUSIP
- 53220K504
- ISIN
- US53220K5048
- Created
- 07/12/2025, 05:03:25
- Last update
- 23/09/2026, 00:33:10
Track Ligand Pharmaceuticals Incorporated with an AI analyst
See which prediction-market events move LGND, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned?
The Motley Fool • STOCK • 14/06/2026, 09:00:01
A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million
The Motley Fool • STOCK • 07/06/2026, 10:28:38
Ligand to Participate in June Investor Conferences
GlobeNewsWire • STOCK • 27/05/2026, 18:01:00
Ligand Reports First Quarter 2026 Financial Results
GlobeNewsWire • STOCK • 07/05/2026, 09:00:00
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
GlobeNewsWire • STOCK • 06/05/2026, 10:01:00
Ligand to Participate in May Investor Conferences
GlobeNewsWire • STOCK • 05/05/2026, 18:01:00
Ligand Pharmaceuticals Incorporated (LGND) M&A Call Transcript
Seeking Alpha • STOCK • 27/04/2026, 12:01:32
Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million
WSJ • STOCK • 27/04/2026, 08:00:00
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
GlobeNewsWire • STOCK • 14/04/2026, 09:00:00
CLO Sells LGND 5,000 Shares for $1.0 Million
The Motley Fool • STOCK • 30/03/2026, 21:41:05
Ligand Pharma CFO Sells $688K in Stock as Shares Surge 80% This Past Year. Here's What to Know
The Motley Fool • STOCK • 27/03/2026, 20:20:10
Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says
Proactive Investors • STOCK • 11/03/2026, 14:51:09